{"filings":[{"id":677756,"accession_number":"0000920148-26-000147","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-05-27T12:04:15+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to present at Jefferies Global Healthcare Conference on June 3, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Presentation scheduled for June 3, 2026, 12:15-12:45 pm ET in New York.","Live webcast accessible via Labcorp investor relations website; archive available for 90 days.","No financial results or new guidance disclosed; routine investor conference appearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":667359,"accession_number":"0000920148-26-000143","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-05-26T20:01:56+00:00","items":["5.07"],"status":"ready","headline":"Labcorp shareholders elect 11 directors, approve say-on-pay, ratify Deloitte at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected: Garheng Kong received 50.1M for, 20.1M against (29% opposed); others received >90% support.","Advisory vote on executive compensation passed with 66.5M for, 3.7M against (94.7% of votes cast).","Ratification of Deloitte & Touche as FY2026 auditor approved with 76.3M for, 53.6K against.","Meeting held May 21, 2026; quorum of 76.4M shares (93% of 82.2M outstanding) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99767,"accession_number":"0000920148-26-000135","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q1 revenue $3.54B (+5.8%), adjusted EPS $4.25 (+10.6%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 diluted EPS $3.35 (+32.8% YoY); adjusted EPS $4.25 vs $3.84 consensus.","FY2026 guidance raised: revenue growth 5.0%–6.1%, Adj. EPS $17.70–$18.35 (midpoint $18.03, +$0.13).","Diagnostics revenue $2.76B (+5.0%); adjusted margin 16.6% (+30bps). Biopharma Labs revenue $780.6M (+8.2%).","Operating cash flow $191.5M (vs $18.5M); free cash flow $70.5M (vs -$107.5M).","Completed acquisition of Crouse Health lab assets; partnerships with CHOP, Illumina, Optum.ai, PathAI."],"consensus_eps_estimate":null,"consensus_eps_actual":3.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":3537600000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99766,"accession_number":"0000920148-26-000131","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares $0.72 quarterly dividend; payable June 11, 2026","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.72 per share declared by Board of Directors.","Payable on June 11, 2026 to shareholders of record May 29, 2026.","No change in dividend rate indicated; continues regular quarterly payout.","Ticker: LH, listed on NYSE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115964,"accession_number":"0000920148-26-000128","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to announce Q1 2026 earnings on April 30, 2026 before market open","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Earnings release scheduled for April 30, 2026 before market open, conference call at 9:00 a.m. ET.","Webcast and replay available on Labcorp investor relations website for one year.","No preliminary financial results or guidance provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115963,"accession_number":"0001193125-26-117879","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Labcorp enters $750M senior unsecured term loan due 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$750M term loan fully funded on March 20, 2026; matures March 20, 2028.","Floating rate: SOFR + 0.70% or base rate + 0.00% per annum.","Financial covenant: max leverage ratio 4.0:1 (can increase to 4.5:1 for four quarters post-acquisition).","Covenants restrict subsidiary debt, liens, mergers, and asset sales with standard exceptions.","Proceeds used for general corporate purposes; lenders include Wells Fargo and PNC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115962,"accession_number":"0000920148-26-000098","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q4 revenue $3.52B (+5.6% YoY), adj EPS $4.07 beat; guides FY26 adj EPS $17.55-18.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $3.52B (up 5.6% YoY, organic 3.8%); diluted EPS $1.98; adjusted EPS $4.07 vs $3.45.","Full-year 2025 revenue $13.95B (+7.2% YoY); adj EPS $16.44 (+12.8% YoY); free cash flow $1.21B.","2026 guidance: revenue $14.61-14.79B (midpoint +5.4%), adj EPS $17.55-18.25 (midpoint +8.9%), FCF $1.24-1.36B.","Diagnostics revenue $2.73B (+5.5%); adj op margin 15.4% (up 150 bps). Biopharma Central Labs grew 11.1%.","Repurchased $450M stock in 2025; declared $0.72/share dividend payable Mar 12, 2026; signed 13 lab partnership deals."],"consensus_eps_estimate":null,"consensus_eps_actual":10.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":13951700000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115961,"accession_number":"0000920148-26-000019","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Labcorp appoints John H. Sampson, M.D., Ph.D., to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed John H. Sampson, M.D., Ph.D., to Board of Directors, effective February 9, 2026.","Dr. Sampson is vice chancellor for health affairs and dean at CU Anschutz School of Medicine.","He brings expertise in oncology, neuroscience, women's health, and personalized medicine.","Previously senior vice president at Duke Health Integrated Practice.","Will serve on the Quality and Compliance Committee of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115960,"accession_number":"0000920148-26-000017","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Labcorp extends receivables purchase agreement to Jan 2029, adds $125M accordion facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Termination date extended to January 26, 2029.","New $125M accordion allows facility increase from $700M up to $825M, exercisable until May 29, 2026.","0.10% SOFR adjustment removed from yield calculation on daily 1M SOFR or term SOFR rate.","Off-balance sheet vehicle Labcorp Receivables LLC is a separate legal entity; its assets not available to parent creditors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115959,"accession_number":"0000920148-26-000013","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to release Q4 2025 earnings on Feb 17, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Earnings release before market open on Tuesday, February 17, 2026.","Conference call and webcast at 9:00 a.m. ET same day.","Replay available until February 4, 2027.","No financial results provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115958,"accession_number":"0000920148-26-000009","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares quarterly cash dividend of $0.72 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.72 per share declared by Board of Directors.","Payable on March 12, 2026 to stockholders of record as of Feb 27, 2026.","This is a routine quarterly dividend declaration; amount unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132373,"accession_number":"0000920148-25-000125","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to Participate in Fireside Chat at 44th Annual J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Labcorp (NYSE: LH) will speak in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 4:30 p.m. PT.","A live audio webcast of the event will be available on the Company's investor relations website at ir.Labcorp.com and archived for replay.","The announcement was made via a press release on December 30, 2025, furnished as Exhibit 99.1 to the Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132372,"accession_number":"0000920148-25-000123","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Labcorp EVP, President of Diagnostics Labs & COO Mark Schroeder to retire April 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Schroeder notified Labcorp of retirement effective April 1, 2026.","Schroeder serves as EVP, President of Diagnostics Laboratories and COO.","No successor has been announced; search process not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132371,"accession_number":"0000920148-25-000120","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Labcorp announces retirement of board member Dr. D. Gary Gilliland","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gilliland will retire from the Labcorp board effective December 31, 2025.","He served on the board since 2014 and was on the Audit Committee and Quality and Compliance Committee.","Gilliland is President and Director Emeritus of Fred Hutchinson Cancer Center, former Merck SVP.","Board thanked him for over 10 years of service; no replacement named yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132370,"accession_number":"0000920148-25-000111","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Labcorp appoints Novartis U.S. President Victor Bulto to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Victor Bulto appointed to Labcorp's Board effective December 1, 2025; he is President of Novartis U.S. and member of Novartis Executive Committee.","Bulto brings 25 years of healthcare experience and oversees Novartis' $20B+ U.S. business across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.","CEO Adam Schechter stated Bulto's expertise in therapeutic areas and transformation will support Labcorp's innovation and long-term growth strategy.","Bulto will receive compensation consistent with Labcorp's director compensation program as described in the April 4, 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132369,"accession_number":"0000920148-25-000093","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q3 adjusted EPS $4.18 vs $3.50; raises FY adjusted EPS midpoint to $16.15-$16.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.56B (+8.6% YoY); diluted EPS $3.12 (vs $2.00); adjusted EPS $4.18 (vs $3.50).","Full-year guidance: revenue growth 7.4%-8.0% (midpoint lowered 40 bps), adjusted EPS $16.15-$16.50 (midpoint +$0.05).","Free cash flow 9M 2025 $715.7M; FY guidance raised to $1.17B-$1.29B.","Acquired oncology assets from BioReference, signed deals with Empire City Labs, Laboratory Alliance, and Crouse Health.","Quarterly dividend $0.72/share payable Dec 11, 2025; repurchased $25M stock in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":8.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":10435900000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132368,"accession_number":"0000920148-25-000091","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares quarterly cash dividend of $0.72 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.72 per share declared by Labcorp's Board of Directors.","Payable on December 11, 2025 to stockholders of record as of November 26, 2025.","Amount unchanged from prior quarterly dividend; no special dividend announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148949,"accession_number":"0000920148-25-000088","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp schedules Q3 2025 earnings release for October 28 before market open","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Earnings results will be released before market open on Tuesday, October 28, 2025.","Conference call and webcast at 9 a.m. ET same day; dial-in registration required.","Webcast replay available from ~2 hours after call until October 15, 2026.","No financial results or guidance included in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148948,"accession_number":"0000920148-25-000085","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp management to present at Morgan Stanley Healthcare Conference on Sept 9","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Executive management team to speak at Morgan Stanley 23rd Annual Global Healthcare Conference.","Fireside chat scheduled for Tuesday, September 9 at 7:45 am ET.","Live audio webcast available on ir.Labcorp.com with replay archived."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148947,"accession_number":"0000920148-25-000075","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q2 revenue $3.53B, Adj EPS $4.35; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $3.53B (+9.5% YoY); diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94.","Full-year guidance raised: revenue growth 7.5%-8.6%; adjusted EPS $16.05-$16.50; FCF $1.13-$1.28B.","Diagnostics Labs revenue $2.75B (+8.9%); Biopharma Lab Services $784.8M (+11.0%).","Quarterly dividend $0.72/share declared; $200M stock repurchased in Q2.","Announced acquisitions of select assets from Incyte Diagnostics, BioReference Health, and Community Health Systems."],"consensus_eps_estimate":null,"consensus_eps_actual":5.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":6872400000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148946,"accession_number":"0000920148-25-000073","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares $0.72/share quarterly dividend payable Sept 11, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.72 per share of common stock declared by Board of Directors.","Payable on September 11, 2025, to stockholders of record as of August 28, 2025.","Routine quarterly dividend declaration; no change in per-share amount indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167883,"accession_number":"0001193125-25-151281","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Labcorp enters $1B revolving credit facility maturing 2030, extending prior facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1B senior unsecured revolver replaces prior facility maturing April 2026; now matures June 27, 2030.","No borrowings outstanding at closing; option to increase facility by up to $500M subject to lender commitments.","Interest rate: SOFR-based plus 0.805%-1.300% or base rate plus 0%-0.300% depending on debt ratings.","Financial covenant: leverage ratio ≤ 4.0:1 (can increase to 4.5:1 for 4 quarters after material acquisition).","Facility fee ranges from 0.070% to 0.200% based on debt ratings, payable quarterly regardless of usage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167882,"accession_number":"0000920148-25-000071","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to announce Q2 2025 earnings on July 24, 2025; no results yet","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Earnings release scheduled for before market open on July 24, 2025.","Conference call and webcast at 9 a.m. ET on July 24.","No preliminary financial data or guidance provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167881,"accession_number":"0000920148-25-000069","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Labcorp shareholders re-elect all 10 directors, approve 2025 equity plans","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 directors elected with high majority; e.g., CEO Schechter received 64.4M for, 5.6M against.","Advisory say-on-pay approved with 64.1M for, 5.6M against.","2025 Omnibus Incentive Plan approved: 66.0M for, 3.9M against.","2025 Employee Stock Purchase Plan approved: 69.9M for, 0.1M against.","Ratification of Deloitte as auditor for 2025: 75.7M for, 0.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167880,"accession_number":"0000920148-25-000064","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp schedules annual shareholder meeting webcast for May 15, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting will be webcast live on May 15, 2025 at 9:00 a.m. ET.","Webcast available on Labcorp Investor Relations website; replay archived for one year.","No other material business or financial results announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167879,"accession_number":"0000920148-25-000054","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q1 revenue $3.35B (+5.3% YoY), adj. EPS $3.84 vs $3.68; raises midpoint of FY adj. EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.35B, GAAP diluted EPS $2.52 (down from $2.69), adjusted EPS $3.84 (up from $3.68).","Raised adjusted EPS guidance midpoint to $15.70–$16.40; revenue and free cash flow guidance reaffirmed.","Diagnostics segment revenue $2.63B (+6.0%), adjusted operating margin 16.3% (down 60bps due to Invitae and weather).","Biopharma segment revenue $721.3M (+1.5%), adjusted operating margin 14.8% (up 80bps).","Announced acquisitions of BioReference Health oncology assets and Inspira Health lab management; new liquid biopsy test Labcorp Plasma Complete."],"consensus_eps_estimate":null,"consensus_eps_actual":2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":3345100000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167878,"accession_number":"0000920148-25-000047","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares $0.72 per share quarterly dividend payable June 11","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.72 per share on common stock.","Payable on June 11, 2025 to stockholders of record as of May 29, 2025.","Dividend declared by Board of Directors on April 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185125,"accession_number":"0000920148-25-000044","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to report Q1 2025 earnings on April 29 before market open","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Earnings release before market open Tuesday, April 29, 2025; conference call at 9 a.m. ET.","Webcast and dial-in details available on Labcorp Investor Relations website.","Replay available until April 16, 2026 approximately two hours after live event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185124,"accession_number":"0000920148-25-000021","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q4 revenue $3.33B (+9.8% YoY); adj. EPS $3.45; FY2025 rev. midpoint ~$14.0B, adj. EPS $16.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $3.33B (+9.8% YoY); diluted EPS $1.70 vs ($1.95); adjusted EPS $3.45 vs $3.30; free cash flow $665.1M vs $412.4M.","Full year 2024 revenue $13.01B (+7.0%); diluted EPS $8.84 vs $4.33; adjusted EPS $14.57 vs $13.56; free cash flow $1.10B vs $748.7M.","Diagnostics Labs segment Q4 revenue $2.59B (+10.2%); Biopharma Lab Services revenue $767.0M (+10.4%).","FY2025 guidance: revenue $13.88B-$14.05B (midpoint +7.4%), adjusted EPS $15.60-$16.40 (midpoint +9.8%), free cash flow $1.10B-$1.25B.","Board declared $0.72 quarterly dividend payable March 12, 2025; $839M spent on acquisitions in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":8.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":13008900000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185123,"accession_number":"0000920148-25-000017","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Labcorp upsizes receivables facility from $300M to $700M, adds TD Bank and MUFG as purchasers","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Facility limit increased from $300M to $700M under amended Receivables Purchase Agreement.","The Toronto-Dominion Bank added as committed purchaser with commitment through Jan 30, 2026.","MUFG Bank and its conduit purchasers joined; their loans may accrue at CP Rate plus applicable margin.","Other purchasers' interest rate unchanged: daily/term SOFR plus 0.10% or base rate, plus margin.","Labcorp Receivables LLC remains a separate entity; its assets not available to Labcorp creditors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185122,"accession_number":"0000920148-25-000013","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to present at J.P. Morgan Healthcare Conference on Jan 14 at 3:45 p.m. PT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Labcorp executive management team will participate in a fireside chat on Jan 14, 2025 at 3:45 p.m. PT.","Event is at the 43rd Annual J.P. Morgan Healthcare Conference.","Live audio webcast via ir.Labcorp.com; archive replay available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185121,"accession_number":"0000920148-25-000008","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares $0.72 quarterly dividend, payable March 12, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Cash dividend of $0.72 per common share declared by Board.","Payable March 12, 2025 to shareholders of record February 27, 2025.","Ticker LH; dividend consistent with prior quarterly rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185120,"accession_number":"0000920148-25-000006","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to report Q4 2024 earnings on February 6, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Earnings release before market open on Thursday, February 6, 2025.","Conference call and webcast at 9 a.m. ET on February 6.","Replay available until January 24, 2026 on IR website.","No financial results disclosed in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201734,"accession_number":"0000920148-24-000121","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Labcorp names Julia Wang CFO effective Dec 2; Glenn Eisenberg to retire April 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julia Wang, former CFO of BeiGene, appointed EVP and CFO of Labcorp effective Dec 2, 2024.","Glenn Eisenberg to retire April 30, 2025; remains special advisor to CEO through April 2025.","Eisenberg oversaw ~100 acquisitions totaling ~$11B and more than doubled Labcorp revenues during his decade as CFO.","Wang receives $725K base salary, 100% target bonus, $400K sign-on bonus, and $3.2M in equity grants.","Wang previously held CFO/senior finance roles at BeiGene, Alexion, Quest Diagnostics, J&J, and PepsiCo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201733,"accession_number":"0000920148-24-000115","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q3 revenue $3.28B, adj EPS $3.50 vs $3.38; lowers FY adj EPS midpoint $0.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.28B (+7.4% YoY); diluted EPS from cont ops $2.00 vs $2.11; adj EPS $3.50 vs $3.38.","FY 2024 adj EPS midpoint lowered $0.10 to $14.30-$14.70 on ~$0.15 weather hit; FCF $161.5M.","Diagnostics revenue $2.55B (+8.9% YoY), base business organic 5.7%; Biopharma rev $737.7M (+2.6%).","Announced acquisitions of Ballad Health outreach assets, Lab Works, and Naples lab mgmt; closed Invitae and BioReference Health purchases.","Quarterly dividend $0.72/share declared, payable Dec 13, 2024 to holders of record Nov 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":7.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":9679500000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201732,"accession_number":"0000920148-24-000111","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares quarterly cash dividend of $0.72 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.72 per share on common stock, payable December 13, 2024.","Record date for stockholders is close of business on November 26, 2024.","Dividend declared by Board of Directors on October 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217726,"accession_number":"0000920148-24-000109","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp schedules Q3 2024 earnings release for October 24, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2024 results will be released before market open on Thursday, October 24, 2024.","Conference call and webcast at 9 a.m. ET on October 24 with management discussing results.","Earnings press release and financial info to be posted on Labcorp Investor Relations website.","Replay available until September 10, 2025 via the Investor Relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217725,"accession_number":"0001193125-24-223695","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Labcorp issues $2B in three tranches to refinance near-term debt maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $650M 4.350% notes due 2030, $500M 4.550% notes due 2032, $850M 4.800% notes due 2034.","Net proceeds ~$1.982B to redeem 2.300% notes due 2024, 3.600% notes due 2025, and $350M revolver borrowings.","Interest payable semi-annually from April 1, 2025; notes redeemable at make-whole premium before respective par call dates.","Notes are senior unsecured obligations guaranteed by Labcorp Holdings Inc.; covenants limit liens and subsidiary debt.","Offering completed under effective shelf registration; underwritten public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217724,"accession_number":"0001193125-24-221373","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Labcorp subsidiary prices $2B senior notes offering to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Labcorp subsidiary (LCAH) prices $2B in three senior note tranches: $650M at 4.350% due 2030, $500M at 4.550% due 2032, $850M at 4.800% due 2034.","Net proceeds to redeem $400M of 2.30% notes due Dec 2024 and $1B of 3.60% notes due Feb 2025, plus repay $350M revolver.","Closing expected Sept 23, 2024; Labcorp provides full and unconditional guarantee of notes.","Notes issued at slight discount: 2030 at 99.931%, 2032 at 99.608%, 2034 at 99.755% of par."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217723,"accession_number":"0000920148-24-000106","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp management to speak at Baird Healthcare Conference on Sept 10","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Labcorp (LH) executive management will present at Baird 2024 Global Healthcare Conference.","Presentation scheduled for Tuesday, September 10, 2024 at 3:10 p.m. ET.","The presentation is part of routine investor outreach; no financial results disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217722,"accession_number":"0000920148-24-000103","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Labcorp enters $300M accounts receivable securitization; accordion to $700M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Three-year $300M securitization facility with PNC Bank, dated August 23, 2024.","Accordion feature allows increase to $700M upon certain conditions.","Labcorp Receivables LLC, a wholly owned SPV, sells/pledges receivables to purchasers.","Labcorp Holdings guarantees performance of originators and servicer, but not collectability.","Interest accrues at SOFR plus 0.10% adjustment and applicable margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217721,"accession_number":"0000920148-24-000096","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q2 revenue $3.22B (+6.2%), adj EPS $3.94; raises revenue guidance, boosts buyback $1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $3.22B (+6.2% YoY); diluted EPS $2.43 vs $1.74; adjusted EPS $3.94 vs $3.42.","Free cash flow $432.9M vs $58.2M a year ago.","Updated FY 2024 guidance: revenue growth 6.4%-7.5% (prior 4.8%-6.4%); adj EPS $14.30-$14.90 (incl. ~$0.40 Invitae dilution).","Board approved $1.0B increase in share repurchase authorization to $1.4B; quarterly dividend $0.72/share.","Invitae acquisition expected close early August; launched FDA-approved hemophilia B CDx and preeclampsia screening."],"consensus_eps_estimate":null,"consensus_eps_actual":5.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":6397500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217720,"accession_number":"0000920148-24-000093","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp declares $0.72 quarterly dividend payable Sept 13, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.72 per share declared.","Payable on September 13, 2024 to holders of record as of August 29, 2024.","Dividend continues Labcorp's regular quarterly payout program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217719,"accession_number":"0000920148-24-000090","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp announces Q2 2024 earnings release and conference call date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Results to be released before market open on August 1, 2024.","Conference call and webcast at 9 a.m. ET on August 1, 2024.","Earnings press release and financial information will be posted on Labcorp Investor Relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237624,"accession_number":"0000920148-24-000087","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp Holdings to Present at 44th Annual William Blair Growth Stock Conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Executive management team will present at the 44th Annual William Blair Growth Stock Conference on June 4, 2024.","Presentation is scheduled for 2:00 p.m. Central Time.","Presentation materials are included as an exhibit to the regulatory filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237623,"accession_number":"0000920148-24-000085","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp to Present at 44th Annual William Blair Growth Stock Conference on June 4, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Labcorp (NYSE: LH) announced executive management will present at the 44th Annual William Blair Growth Stock Conference.","Presentation scheduled for Tuesday, June 4, 2024 at 2:00 p.m. (CT).","Press release issued May 28, 2024 as Exhibit 99.1 to Form 8-K filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237622,"accession_number":"0000920148-24-000063","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K12B","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","2.03","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Labcorp completes holding company reorganization; Labcorp Holdings becomes new public parent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Labcorp Holdings Inc. becomes successor issuer; shares convert 1:1 from Labcorp common stock.","LH ticker continues on NYSE uninterrupted; new CUSIP 504922105.","Directors, executive officers, and business operations unchanged; no change in control.","Labcorp Holdings guarantees Labcorp's senior notes and credit agreement via supplemental indenture and guarantor joinder.","Labcorp's authorized shares reduced to 1,000 common and 250 preferred; Labcorp Holdings authorized shares at 265M common and 30M preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237628,"accession_number":"0000920148-24-000036","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LabCorp annual meeting: directors elected, say-on-pay approved, two shareholder proposals fail","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Kathryn E. Wengel received 45.5M for, 25.2M against (largest opposition).","Advisory say-on-pay passed with 65.0M for (vs 5.6M against, 0.2M abstain).","Ratification of Deloitte as auditor approved: 76.1M for, 0.8M against.","Shareholder proposal on golden parachute vote defeated: 65.5M against, 5.2M for.","Proposal on nonhuman primate transport report also defeated: 64.1M against, 5.8M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237627,"accession_number":"0000920148-24-000034","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Labcorp announces annual meeting webcast for May 14, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting webcast live on May 14, 2024 at 9:00 a.m. ET.","Available on Labcorp Investor Relations website; archived replay for one year.","No financial or operational results disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237626,"accession_number":"0000920148-24-000029","cik":920148,"company_name":"LABCORP HOLDINGS INC.","ticker":"LH","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Labcorp Q1 adj EPS $3.68 vs $3.46 YoY; raises FY guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.18B (+4.6% YoY); organic base business grew 6.7%.","Diluted EPS $2.69 vs $2.34; adjusted EPS $3.68 vs $3.46.","FY2024 adjusted EPS guidance raised to $14.45-$15.35 (prev $14.30-$15.40); FCF reaffirmed $1.0-$1.15B.","Acquisitions: selected Invitae assets, agreed to buy BioReference Health diagnostic assets, closed three deals including Baystate Health and Providence.","New holding company structure May 17; Labcorp Holdings Inc. replaces Labcorp as public entity; ticker LH unchanged; $0.72 dividend payable June 12."],"consensus_eps_estimate":null,"consensus_eps_actual":2.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":3176600000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21176501000.22538,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-04-25T23:59:59+00:00|237626"}